Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Theodore Phillips

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 23, 2011
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosisJ Theodore Phillips, Gavin Giovannoni, Fred D Lublin, et al.
Current Medical Research and Opinion|October 18, 2013
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safetyRobert J Fox, Mariko Kita, Stanley L Cohan, et al.
International Journal of MS Care|October 17, 2015
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl FumarateJ Theodore Phillips, Krzysztof Selmaj, Ralf Gold, et al.
Journal of Neurology|June 11, 2013
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM studyMichael Hutchinson, Robert J Fox, David H Miller, et al.
Clinical Therapeutics|March 11, 2018
Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971]Mariko Kita, Robert J Fox, Ralf Gold, et al.
Neurology and Therapy|November 4, 2015
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi StudyJ Theodore Phillips, April A Erwin, Stephanie Agrella, et al.
Clinical Therapeutics|October 16, 2014
Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studiesMariko Kita, Robert J Fox, Ralf Gold, et al.
Archives of Neurology|July 11, 2007
High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytesOlaf Stüve, Petra D Cravens, Mahendra P Singh, et al.
Journal of Neurology|October 20, 2011
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MSBianca Weinstock-Guttman, Steven L Galetta, Gavin Giovannoni, et al.
The New England Journal of Medicine|September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisRobert J Fox, David H Miller, J Theodore Phillips, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 23, 2011
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosisJ Theodore Phillips, Gavin Giovannoni, Fred D Lublin, et al.
Current Medical Research and Opinion|October 18, 2013
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safetyRobert J Fox, Mariko Kita, Stanley L Cohan, et al.
International Journal of MS Care|October 17, 2015
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl FumarateJ Theodore Phillips, Krzysztof Selmaj, Ralf Gold, et al.
Journal of Neurology|June 11, 2013
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM studyMichael Hutchinson, Robert J Fox, David H Miller, et al.
Clinical Therapeutics|March 11, 2018
Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971]Mariko Kita, Robert J Fox, Ralf Gold, et al.
Neurology and Therapy|November 4, 2015
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi StudyJ Theodore Phillips, April A Erwin, Stephanie Agrella, et al.
Clinical Therapeutics|October 16, 2014
Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studiesMariko Kita, Robert J Fox, Ralf Gold, et al.
Archives of Neurology|July 11, 2007
High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytesOlaf Stüve, Petra D Cravens, Mahendra P Singh, et al.
Journal of Neurology|October 20, 2011
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MSBianca Weinstock-Guttman, Steven L Galetta, Gavin Giovannoni, et al.
The New England Journal of Medicine|September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisRobert J Fox, David H Miller, J Theodore Phillips, et al.
Pageof 5